Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) mutations. Current treatment options for MPNs include cytoreduction by hydroxyurea and JAK1/2 inhibition by ruxolitinib, both of which are not curative. We show here that cell lines expressing JAK2(V617F), MPL(W5...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Nieborowska-Skorska, Margaret, Maifrede, Silvia, Dasgupta, Yashodhara, Sullivan, Katherine, Flis, Sylwia, Le, Bac Viet, Solecka, Martyna, Belyaeva, Elizaveta A., Kubovcakova, Lucia, Nawrocki, Morgan, Kirschner, Martin, Zhao, Huaqing, Prchal, Josef T., Piwocka, Katarzyna, Moliterno, Alison R., Wasik, Mariusz, Koschmieder, Steffen, Green, Tony R., Skoda, Radek C., Skorski, Tomasz
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746670/
https://ncbi.nlm.nih.gov/pubmed/29042365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-784942
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars